A01K 2207/00
Modified animals
A01K2207/00 (Modified animals) appears on 1,712 US grants and 2,971 published applications in this corpus.
Search patents in A01K- Granted patents
- 1,712
- Published applications
- 2,971
- Assignees
- 1,264
- Inventors
- 5,449
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 2 | 0 |
| 1994 | 3 | 0 |
| 1995 | 5 | 0 |
| 1996 | 19 | 0 |
| 1997 | 37 | 0 |
| 1998 | 58 | 0 |
| 1999 | 50 | 0 |
| 2000 | 55 | 0 |
| 2001 | 50 | 7 |
| 2002 | 40 | 69 |
| 2003 | 46 | 112 |
| 2004 | 24 | 86 |
| 2005 | 22 | 62 |
| 2006 | 41 | 58 |
| 2007 | 31 | 51 |
| 2008 | 32 | 48 |
| 2009 | 27 | 78 |
| 2010 | 38 | 67 |
| 2011 | 26 | 106 |
| 2012 | 29 | 87 |
| 2013 | 35 | 93 |
| 2014 | 51 | 103 |
| 2015 | 74 | 129 |
| 2016 | 73 | 149 |
| 2017 | 77 | 141 |
| 2018 | 74 | 130 |
| 2019 | 77 | 159 |
| 2020 | 87 | 201 |
| 2021 | 98 | 212 |
| 2022 | 80 | 204 |
| 2023 | 84 | 170 |
| 2024 | 96 | 194 |
| 2025 | 95 | 155 |
| 2026 | 71 | 100 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A01K 2207/15Humanized animalsIndexing code1,165
- A01K 2207/12Animals modified by administration of exogenous cellsIndexing code362
- A01K 2207/05Animals modified by non-integrating nucleic acidsIndexing code136
- A01K 2207/20Animals treated with compounds which are neither proteins nor nucleic acidsIndexing code75
- A01K 2207/30Animals modified by surgical methodsIndexing code54
- A01K 2207/10Animals modified by protein administration, for non-therapeutic purposeIndexing code40
- A01K 2207/25Animals on a special dietIndexing code36
- A01K 2207/35Animals modified by environmental factorsIndexing code22
Recent patents
- Non-human animals having humanized Fc-gamma receptors29 Sep 2026US 12,745,761 B2Regeneron Pharmaceuticals, Inc.
- Genetically modified non-human animal with human or chimeric TFR122 Sep 2026US 12,740,550 B2Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Methods of treating mitochondrial disorders1 Sep 2026US 12,723,062 B2The Regents of the University of California
- Fullerenes to treat diseases and conditions25 Aug 2026US 12,714,679 B2The Cleveland Clinic Foundation
- Methods and compositions for the expression of constitutively active RAP1A from a VMD2 promoter25 Aug 2026US 12,714,757 B2University of Flordia Research Foundation, Inc.
- Humanized ace2-expressing transgenic mouse susceptible to sars-cov-2 virus infection and method for producing same8 Oct 2026US 2026/0305587 A1Seoul National University R&Db Foundation
- Genetically Modified Non-Human Animals and Methods of Use Thereof8 Oct 2026US 2026/0305588 A1Institute for Research in Biomedicine (IRB)
- Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse8 Oct 2026US 2026/0308532 A1Fred Hutchinson Cancer Center
- Verification of methane abatement in animals1 Oct 2026US 2026/0293863 A1Commonwealth Scientific and Industrial Research Organisation
- Methods and compositions for insertion of antibody coding sequences into a safe harbor locus1 Oct 2026US 2026/0297613 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Production of antibodies from transgenic animals1,567US 5,545,807 AMedical Research Council · 1996